Gilead Sciences (XTER:GIS) Construction In Progress : €0 Mil (As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Gilead Sciences Construction In Progress?

Gilead Sciences's quarterly construction in progress increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€478 Mil) but then declined from Dec. 2024 (€478 Mil) to Mar. 2025 (€0 Mil).

Gilead Sciences's annual construction in progress declined from Dec. 2022 (€679 Mil) to Dec. 2023 (€606 Mil) and declined from Dec. 2023 (€606 Mil) to Dec. 2024 (€478 Mil).

Gilead Sciences Construction In Progress Historical Data

The historical data trend for Gilead Sciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Construction In Progress Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

703.63

935.45

678.74

606.14

478.46

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															-	-	-	478.46	-

Gilead Sciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XTER:GIS) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GILD:Canada GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).